Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from …
JT Merrill, RF Van Vollenhoven, JP Buyon… - Annals of the rheumatic …, 2016 - Elsevier
Objectives To evaluate the efficacy and safety of tabalumab, a human IgG4 monoclonal
antibody that neutralises membrane and soluble B-cell activating factor (BAFF). Methods
This randomised, placebo-controlled study enrolled 1124 patients with moderate-to-severe
systemic lupus erythematosus (SLE)(Safety of Estrogens in Lupus Erythematosus National
Assessment-SLE Disease Activity Index≥ 6 at baseline). Patients received standard of care
plus subcutaneous study drug, starting with a loading dose (240 mg) at week 0 and followed …
antibody that neutralises membrane and soluble B-cell activating factor (BAFF). Methods
This randomised, placebo-controlled study enrolled 1124 patients with moderate-to-severe
systemic lupus erythematosus (SLE)(Safety of Estrogens in Lupus Erythematosus National
Assessment-SLE Disease Activity Index≥ 6 at baseline). Patients received standard of care
plus subcutaneous study drug, starting with a loading dose (240 mg) at week 0 and followed …